News
-
Graceway Pharmaceuticals, which manufactures the MaxAir Autohaler pirbuterol acetate MDI, one of the last remaining CFC-propelled metered dose inhalers, has agreed to sell all of its assest to Galderma, a ” company focused exclusively on… Read more . . .
-
Massachusetts biotech company Pulmatrix presented data from two studies of its Pulmatrix presents data from preclinical studies of its lead product, PUR118, an inhaled cationic airway lining modulator (iCALM) for the treatment of respiratory diseases… Read more . . .
-
Novartis has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for its NVA237 glycopyrronium bromide dry powder inhaler, which will be called the Seebri Breezhaler. The MAA once-daily long-acting antimuscarinic (LAMA)… Read more . . .
-
Almirall has presented a number of posters at the 2011 Annual Congress of the European Respiratory Society (ERS), including, for the first time, full data from the six-month Phase 3 ATTAIN study of its aclidinium… Read more . . .
-
MicroDose Therapeutx has initiated a Phase 1 clinical trial of MDT-637, an inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV) that is delivered using the company’s novel dry powder… Read more . . .
-
Former SkyePharma CEO and current Executive Chairman of PolyTherics Ken Cunningham has joined the Board of Directors of inhaled drug developer Prosonix as a Non-Executive Director. Cunningham will also serve as Chair of the Prosonix… Read more . . .
-
Two posters presented by Pearl Therapeutics at the 2011 European Respiratory Society meeting show additional data from a Phase 2b study demonstrating that Pearl’s glycopyrrolate (GP)/fomoterol fumarate (FF) fixed combination metered dose inhaler and its… Read more . . .
-
Shortly after announcing positive Phase 2a results for its glycopyrrolate inhalation solution, Elevation Pharmaceuticals, announced that it has appointed Jaisim Shah as Senior Vice President and Chief Business Officer and Pravin Soni as Senior Vice… Read more . . .
-
Marina Biotech (formerly MDRNA/Nastech) is offering intellectual property related to intranasal formulations of rapid-acting insulin and of parathyroid hormone (PTH) for the treatment of osteoporosis for sale through ICAP Patent Brokerage. ICAP has recently handled… Read more . . .
-
According to Mundipharma, three Phase 3 studies of the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) have demonstrated that the product “had comparable efficacy in improving the lung function and a similar safety profile… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


